fda glp-1 enforcement news warns Novo Nordisk of unreported side effects GLP-1 Safety Check - National

A meta-analysis also reported diagnoses of medullary thyroid carcinoma in patients taking GLP-1RAs, reinforcing the at-risk status as a contraindication to GLP-1RA treatment

Through December 31, 2026, Novo Nordisk is offering eligible self-pay patients new to Wegovy injectables an introductory price of $199 per fill for the first two fills of medication (0.25 mg and 0.5 mg doses only)

however, there is no mention of the practical application of the use of these medications beyond the purpose of decreasing GI symptoms in the perioperative setting

Studies showed that retained gastric fooda common symptomhas only 32-67% positive predictive value depending on the patient population

See the related article at Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake